生长抑素联合美沙拉嗪治疗溃疡性结肠炎的效果及对细胞免疫与凝血指标的影响

Effect of somatostatin combined with mesalazine in the treatment of ulcerative colitis and its effect on cellular immunity and coagulation indexes

目的探讨生长抑素与美沙拉嗪联合治疗溃疡性结肠炎的效果及对细胞免疫与凝血指标的影响。方法选取2018年6月~2020年6月收治的90例溃疡性结肠炎患者作为研究对象,应用随机数字分组法依照1∶1的比例将患者分为观察组与对照组,每组45例。所有患者均行纠正水电解质紊乱、酸碱失衡、改善营养等常规治疗,对照组在常规治疗基础上增加美沙拉嗪口服,观察组在对照组基础上联合生长抑素治疗,对比两组患者的临床治疗效果,治疗前后免疫功能和凝血指标变化以及不良反应发生情况。结果观察组患者治疗总有效率为93.33%,对照组治疗总有效率为75.56%,观察组明显高于对照组(P<0.05);两组患者治疗前CD4^(+)、CD_(3)^(+)、CD4^(+)/CD8^(+)对比无明显差异(P>0.05),治疗后两组患者CD4^(+)、CD_(3)^(+)、CD4^(+)/CD8^(+)均提升,且观察组高于对照组(P<0.05);治疗前两组患者凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、血小板(PLT)、纤维蛋白原(FIB)、一氧化氮(NO)、一氧化氮合酶(NOS)对比无明显差异(P>0.05),治疗后两组患者PT均升高,观察组高于对照组,治疗后PLT、NO、NOS均降低,观察组低于对照组。对照组APTT、FIB治疗前后无明显变化,观察组治疗后APTT升高,FIB降低,且观察组优于对照组(P<0.05);两组患者不良反应发生率对比无明显差异(P>0.05)。结论溃疡性结肠炎应用生长抑素与美沙拉嗪联合治疗能够进一步减轻患者临床症状,治疗效果显著,可提升患者免疫功能与凝血功能,且安全性较高。

Objective To investigate the effect of somatostatin combined with mesalazine in the treatment of ulcerative colitis and its effect on cellular immunity and coagulation indexes.Methods 90 patients with ulcerative colitis treated in our hospital from June 2018 to June 2020 were selected as the research objects.The patients were randomly divided into the observation group and the control group according to the ratio of 1∶1,with 45 cases in each group.All patients were treated with routine treatment such as correcting water electrolyte disorder,acid-base imbalance and improving nutrition.The control group was treated with mesalazine on the basis of routine treatment,and the observation group was treated with somatostatin on the basis of the control group.The clinical treatment effects,changes of immune function,coagulation indexes and adverse reactions of the two groups were compared before and after treatment.Results The total effective rate was 93.33%in the observation group and 75.56%in the control group(P<0.05);There was no significant difference in CD4^(+),CD_(3)+,CD4^(+)/CD8^(+)between the two groups before treatment(P>0.05).After treatment,CD4^(+),CD_(3)^(+),CD4^(+)/CD8^(+)in the two groups increased,and the observation group was higher than that in the control group(P<0.05);Before treatment,there was no significant difference in prothrombin time(PT),thromboplastin time(APTT),platelet(PLT),fibrinogen(FIB),nitric oxide(NO)and nitric oxide synthase(NOS)between the two groups(P>0.05).After treatment,PT increased in the observation group.which was higher than that in the control group.After treatment,PLT,NO and NOS decreased,which was lower in the observation group than that in the control group,There were no significant changes in APTT and FIB in the control group before and after treatment.APTT increased and FIB decreased in the observation group after treatment,and the observation group was better than the control group(P<0.05);There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combined treatment of somatostatin and mesalazine in patients with ulcerative colitis can further reduce the clinical symptoms of patients with significant therapeutic effect,and can improve the immune function and coagulation function of patients with high safety,which is worthy of clinical application and promotion.